Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2021-10-13

FDA Approved: ALLEGRA HIVES 24HR — Supplemental Application (Chattem, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for Allegra Hives 24HR, a fexofenadine hydrochloride product from Chattem, expanding its labeling for hives.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ALLEGRA HIVES 24HR (fexofenadine hydrochloride)

Snippet

SUPPL AP for ALLEGRA HIVES 24HR (FEXOFENADINE HYDROCHLORIDE)